An observational study in MASH, MASLD and MASH With Fibrosis, sponsored by Julius Clinical. Recruiting at 13 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-01.
Sponsored by Julius Clinical · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Liver Cirrhosis with a site in Belgium — 11 open to participants now, 13 under way, 2 of them phase 3. Liver Cirrhosis · Belgium.
Among the 41 studies in Liver Cirrhosis with a site in Belgium, this one has the largest planned enrollment of the 17 observational ones that give a count, is the only one that started in 2023, is one of 17 observational ones, reaches primary completion later than 11 of the 12 other live ones, and was the 33rd registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →11 of the 41 studies in Liver Cirrhosis with a site in Belgium are open now. Recruiting first, the newest first:
Universitair Ziekenhuis Brussel · Sites in Belgium
Ages 18+
University Medical Center Groningen · Sites in Belgium, Austria, Czechia and 9 more countries
Ages 18+
Universitair Ziekenhuis Brussel · Sites in Belgium
Ages 18+
Centre Hospitalier Universitaire Saint Pierre · Sites in Belgium
Ages 18+
Boehringer Ingelheim · Sites in Belgium, United States, Argentina and 34 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 12 · Phase 3 9 · Phase 4 2
First in 2000; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 172 across 528 observational studies indexed under Liver Cirrhosis.
Median enrollment 159 across the 24 interventional studies, 450 across the 17 observational. Of the 25 that completed or were terminated, 6 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 41 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Julius Clinical as lead sponsor.
Julius Clinical has 1 study filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Liver Cirrhosis with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05500222Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | 2026-12 |
| NCT07585890University Medical Center GroningenEstablishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT07238114Universitaire Ziekenhuizen KU LeuvenLiver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors | 2027-07-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 41 studies in Liver Cirrhosis with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
GRIPonMASH will assist (primary) health care providers clinicians to implement the latest patient care pathway, as described by the European Association for the Study of the Liver (EASL), to identify patients at risk of severe metabolic dysfunction-associated steatotic liver disease (MASLD) and to raise awareness. The primary objective is to implement a transmural patient care pathway, in order to identify patients with MASLD and its progressive form metabolic dysfunction-associated steatohepatitis (MASH) in primary care centres and clinics in 10 European countries.
GRIPonMASH is an observational study in which 10.000 high risk patients (type 2 diabetes mellitus, metabolic syndrome, obesity or arterial hypertension) in 10 different European countries will be screened for the presence of MASLD, liver fibrosis and (at-rsik) MASH using at least two non-invasive tests (FIB-4 and FibroScan). Additional published and exploratory non-invasive test will also be investigated. Blood samples and liver biopsy material will be collected. Genomic, proteomic, metabolomic, lipidomic and fluxomic studies will be applied to gain a better understanding of the pathophysiology of MASLD and to identify (bio)markers that will help to detect patients at-risk. The predictive value of FIB-4 in relation to FibroScan results and liver biopsy will be analysed. Long-term follow-up of 5 years in all participants will provide insight into the natural history of the disease.
Male and female patients aged 18-75 years with a current or prior diagnosis of at least one of the following four conditions: type 2 diabetes mellitus or metabolic syndrome or obesity or arterial hypertension. Subjects who meet the inclusion and exclusion criteria will be enrolled at primary care centers in one of the 10 countries.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study definitions:
Type 2 diabetes mellitus
Obesity
Arterial hypertension
Metabolic syndrome
AND any two of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prevalence of liver steatosis and MASLD estimated by FibroScan CAP in patients at risk
Steatosis grade deduced from controlled attenuation parameter (CAP) measurement with Fibroscan
Time frame: Baseline
Prevalence of liver fibrosis estimated by FibroScan LSM in patients at risk
Fibrosis stage deduced from liver stiffness measurement (LSM) by vibration controlled transient elastography (VCTE) measurement with Fibroscan
Time frame: Baseline
Prevalence of at-risk MASH estimated by FAST score in patients at risk
At-risk MASH deduced from FAST score
Time frame: Baseline
*Subset of patients: prevalence of MASH in patients at risk
MASH diagnosis confirmed by histology (NAS/SAF criteria) upon liver biopsy; only in patients with \>12 kPa at 1st FibroScan or \>=8 kPa at 2nd FibroScan
Time frame: 16 or 30 weeks
Comparison of the prevalence of MASLD, liver fibrosis and (at-risk) MASH between the participating countries
Prevalence (see outcome 1-4) stratified per country
Time frame: Baseline (1-3) to 16/30 weeks for biopsy-confirmed MASH (4)
Evaluate added value of a 2-step pathway as compared to FibroScan only for detection of high-risk patients
Number of patients at risk identified by FIB-4 compared to numbers found using LSM by VCTE with FibroScan measurements, and numbers found in combination
Time frame: Baseline
Build diagnostic model to identify MASH patients in a high-risk population
Possible model parameters are all baseline clinical characteristics reported in the eCRF
Time frame: Baseline
Genotypes related to MASH in different European countries: Exploratory
Genomic (GWAS) and proteomic analysis on collected blood samples
Time frame: Baseline
(Non-invasive) metabolite biomarkers identifying MASH in patients at risk: Exploratory
Mass-spectrometry (MS) based metabolomic and lipidomic analyses on collected blood and samples, both targeted and untargeted approaches.
Time frame: Baseline
Prevalence of co-morbidities and associated therapies (especially for CVD) in patients with MASH compared to those without, in high-risk patient populations
Prevalence of comorbidities, medication use, medical history
Time frame: Baseline
Identify prognostic factors/biomarkers for complications in patients with MASLD and MASH by 5 years follow up
Disease progression and liver-related and non-liver related complications
Time frame: Throughout follow-up (at 3 and 5 years)
Patient Reported Outcomes: Dietary habits and lifestyle
14 item Mediterranean Diet Score; lifestyle surveys
Time frame: Baseline + throughout follow-up (at 3 and 5 years)
*Subset of patients: Second FibroScan examination
CAP and LSM by VCTE at 2nd FibroScan examination
Time frame: 14 weeks
Longitudinal changes in liver assessments
Repeated CAP, LSM by VCTE and FAST measurements over time
Time frame: Baseline, 14 weeks + throughout follow-up (at 3 and 5 years)
Not enrolling at this site.
Plan to share: Undecided
Started Jun 2023 (actual). Primary completion is estimated for Mar 2031, 93 months after the start.
Of 247 observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 93 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.